Sun Pharma Advanced Research Co Ltd

In a regulatory filing, SPARC said that its partner, Sun Pharmaceutical Industries (SPIL), reported top-line results from Phase 2 studies of Vibozilimod (SCD-044), a drug candidate aimed at treating moderate-to-severe psoriasis and atopic dermatitis. Both trials failed to meet their primary endpoints: a 75% improvement in the Psoriasis Area and Severity Index (PASI75) and Eczema Area and Severity Index (EASI75), respectively, by Week 16. Following the setback, SPARC and SPIL stated they would assess the appropriate next steps for the development of Vibozilimod. SPARC is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. On a consolidated basis, SPARC reported net loss of Rs 59.77 crore in Q4 March 2025 as against net loss of Rs 105.79 crore in Q4 March 2024. Net sales rose 64.19% year-on-year to Rs 27.19 crore in Q4 March 2025. Powered by Capital Market - Live

Aditya Birla Fashion & Retail Ltd, Fusion Finance Ltd Partly Paidup, Alivus Life Sciences Ltd and Indo Count Industries Ltd are among the other losers in the BSE's 'A' group today, 04 June 2025.Sun Pharma Advanced Research Company Ltd lost 18.76% to Rs 158.9 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 9.45 lakh shares were traded on the counter so far as against the average daily volumes of 94359 shares in the past one month.Aditya Birla Fashion & Retail Ltd crashed 10.33% to Rs 77.1. The stock was the second biggest loser in 'A' group.On the BSE, 437.77 lakh shares were traded on the counter so far as against the average daily volumes of 4.25 lakh shares in the past one month.Fusion Finance Ltd Partly Paidup tumbled 3.89% to Rs 100.05. The stock was the third biggest loser in 'A' group.On the BSE, 985 shares were traded on the counter so far as against the average daily volumes of 10093 shares in the past one month.Alivus Life Sciences Ltd dropped 3.48% to Rs 1024. The stock was the fourth biggest loser in 'A' group.On the BSE, 2773 shares were traded on the counter so far as against the average daily volumes of 5155 shares in the past one month.Indo Count Industries Ltd fell 3.43% to Rs 271.3. The stock was the fifth biggest loser in 'A' group.On the BSE, 16635 shares were traded on the counter so far as against the average daily volumes of 54599 shares in the past one month.Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 59.77 crore in the quarter ended March 2025 as against net loss of Rs 105.79 crore during the previous quarter ended March 2024. Sales rose 64.19% to Rs 27.19 crore in the quarter ended March 2025 as against Rs 16.56 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 342.51 crore in the year ended March 2025 as against net loss of Rs 387.21 crore during the previous year ended March 2024. Sales declined 5.00% to Rs 71.77 crore in the year ended March 2025 as against Rs 75.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales27.1916.56 64 71.7775.55 -5 OPM %-195.59-639.07 --450.24-532.23 - PBDT-57.72-102.34 44 -330.39-374.32 12 PBT-60.67-105.41 42 -342.78-386.83 11 NP-59.77-105.79 44 -342.51-387.21 12 Powered by Capital Market - Live

The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors. Antibody'drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumours. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv. Anil Raghavan, CEO of SPARC, said: SBO-154, our first ADC is ready to advance in phase-1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally. Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The scrip had declined 2.63% to end at Rs 148 on the BSE on Friday. Powered by Capital Market - Live

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors. 'SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.' said Anil Raghavan, CEO of SPARC. SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.Powered by Capital Market - Live

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.51 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales14.9113.86 8 OPM %-494.23-740.40 - PBDT-76.30-96.49 21 PBT-79.44-99.65 20 NP-79.51-99.65 20 Powered by Capital Market - Live

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.71 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales14.9113.86 8 OPM %-498.86-740.40 - PBDT-76.96-96.49 20 PBT-79.71-99.65 20 NP-79.71-99.65 20 Powered by Capital Market - Live

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live

The LoI outlines the key terms of license and rights for development and commercialization by Tiller. Under the LoI, SPARC will receive a 55% equity stake in Tiller upon execution of the agreement. The equity will vest in two tranches: 45% upon execution of the license agreement, and the remaining 10% upon the achievement of specific milestones or within 6 months of the agreement's execution. Anil Raghavan, CEO of SPARC, said, 'We are excited about the opportunity to partner with Tiller to advance potential treatment of solid tumors affecting millions each year, with no current cure.' Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The company reported a net loss of Rs 107.28 crore in Q2 FY25 as compared with net loss of Rs 86.08 crore in Q2 FY24. Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Shares of Sun Pharma Advanced Research Company fell 1.45% to Rs 227.15 on the BSE. Powered by Capital Market - Live